HomeImpact ▶ ATS COVID-19 Crisis Fund
ATS COVID-19 Crisis Fund

The ATS gratefully acknowledges the following companies for their generous support:

Boehringer Ingelheim Pharmaceuticals, Inc.



Sanofi Genzyme/Regeneron




NBRC logo.png

Members of the ATS are leading physicians at the frontline of this pandemic, in pulmonology and critical care. This crisis fund will be used to support the Society’s all-encompassing efforts to fight COVID-19.

ATS COVID-19 Crisis Fund Impact Report

Related activities include:

  • Development and dissemination of educational resources based on the very latest information regarding prevention and treatment of COVID-19 and other pulmonary and critical care conditions.
  • Support rapid information collection and dissemination in times of crisis.
  • Develop rapid response capabilities that provide expert recommendations and suggestions to address areas lacking in empirical evidence.
  • Provide resources to clinicians in need of expanding their skill set during this emergency.

For questions or to make a contribution, please contact Michelle Turenne, ATS Chief of Development, at

The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

X Facebook LinkedIn Instagram YouTube Social Media Page

25 Broadway
New York, NY 10004
United States of America

Phone: +1 (212) 315-8600
Fax: +1 (212) 315-6498

© 1998 - American Thoracic Society, all rights reserved.